NO913228L - Antistoffer og fremgangsmaate for deres fremstilling. - Google Patents

Antistoffer og fremgangsmaate for deres fremstilling.

Info

Publication number
NO913228L
NO913228L NO91913228A NO913228A NO913228L NO 913228 L NO913228 L NO 913228L NO 91913228 A NO91913228 A NO 91913228A NO 913228 A NO913228 A NO 913228A NO 913228 L NO913228 L NO 913228L
Authority
NO
Norway
Prior art keywords
antibody
pref
derived
chain
cdr
Prior art date
Application number
NO91913228A
Other languages
English (en)
Other versions
NO316076B1 (no
NO913228D0 (no
Inventor
John Robert Adair
Diljeet Singh Athwal
John Spencer Emtage
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO913228(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of NO913228D0 publication Critical patent/NO913228D0/no
Publication of NO913228L publication Critical patent/NO913228L/no
Publication of NO316076B1 publication Critical patent/NO316076B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19913228A 1989-12-21 1991-08-19 Fremgangsmåte for fremstilling av et terapeutisk aktivt CDR- podet antistoffmolekyl, DNA-molekyl, klonings- eller ekspresjonsvektor samtvertscelle NO316076B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898928874A GB8928874D0 (en) 1989-12-21 1989-12-21 Humanised antibodies
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies

Publications (3)

Publication Number Publication Date
NO913228D0 NO913228D0 (no) 1991-08-19
NO913228L true NO913228L (no) 1991-10-21
NO316076B1 NO316076B1 (no) 2003-12-08

Family

ID=10668300

Family Applications (5)

Application Number Title Priority Date Filing Date
NO91913229A NO913229L (no) 1989-12-21 1991-08-19 Antistoff og fremgangsmaate for dets fremstilling.
NO19913228A NO316076B1 (no) 1989-12-21 1991-08-19 Fremgangsmåte for fremstilling av et terapeutisk aktivt CDR- podet antistoffmolekyl, DNA-molekyl, klonings- eller ekspresjonsvektor samtvertscelle
NO19913271A NO310560B1 (no) 1989-12-21 1991-08-20 Fremgangsmåte for fremstilling av et humanisert OKT 4a antistoff
NO985467A NO985467D0 (no) 1989-12-21 1998-11-23 Antistoff og diagnostisk preparat omfattende dette
NO19985468A NO316074B1 (no) 1989-12-21 1998-11-23 CDR-podet antistoffmolekyl, DNA-molekyl, klonings- eller ekspresjonsvektor,vertscelle samt diagnostisk preparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO91913229A NO913229L (no) 1989-12-21 1991-08-19 Antistoff og fremgangsmaate for dets fremstilling.

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO19913271A NO310560B1 (no) 1989-12-21 1991-08-20 Fremgangsmåte for fremstilling av et humanisert OKT 4a antistoff
NO985467A NO985467D0 (no) 1989-12-21 1998-11-23 Antistoff og diagnostisk preparat omfattende dette
NO19985468A NO316074B1 (no) 1989-12-21 1998-11-23 CDR-podet antistoffmolekyl, DNA-molekyl, klonings- eller ekspresjonsvektor,vertscelle samt diagnostisk preparat

Country Status (21)

Country Link
US (11) US5929212A (no)
EP (5) EP0460167B1 (no)
JP (4) JP3452062B2 (no)
KR (3) KR100197956B1 (no)
AT (4) ATE129017T1 (no)
AU (4) AU646009B2 (no)
BG (1) BG60462B1 (no)
BR (1) BR9007197A (no)
CA (3) CA2046904C (no)
DE (4) DE69020544T2 (no)
DK (4) DK0460178T3 (no)
ES (4) ES2165864T3 (no)
FI (4) FI108777B (no)
GB (4) GB8928874D0 (no)
GR (2) GR3017734T3 (no)
HU (4) HUT60786A (no)
NO (5) NO913229L (no)
RO (3) RO114232B1 (no)
RU (1) RU2112037C1 (no)
WO (3) WO1991009967A1 (no)
ZA (1) ZA9110129B (no)

Families Citing this family (1423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
AU662891B2 (en) * 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9104498D0 (en) * 1991-03-04 1991-04-17 Ks Biomedix Ltd Antibody
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2736076A1 (en) * 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
WO1993012220A1 (en) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0728017A1 (en) * 1993-11-10 1996-08-28 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5702946A (en) * 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2186455A1 (en) * 1994-03-29 1995-10-05 Raymond John Owens Antibodies against e-selectin
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
AU4270596A (en) * 1994-12-23 1996-07-19 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
AU717779C (en) * 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP1161955A3 (en) * 1995-05-18 2001-12-19 Ortho Pharmaceutical Corporation Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
ATE266726T1 (de) 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69638269D1 (de) * 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
JP4503706B2 (ja) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド グリコシル化が改質されたヒト化抗体
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
WO2000020555A2 (en) 1998-10-06 2000-04-13 Aarl Inc Transformation system in the field of filamentous fungal hosts: in chrysosporium
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
DE69836956T2 (de) * 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69832970T2 (de) * 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
IL132240A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
CA2305712A1 (en) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
TR200002885T2 (tr) * 1998-04-03 2000-12-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
EP1073464B1 (en) * 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003509078A (ja) * 1999-09-22 2003-03-11 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 細胞に基づくアッセイ
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
DE60130538T2 (de) * 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP1783227A1 (en) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
JP2003521931A (ja) 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Ｔｎｆファミリーの異種ポリペプチド
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
AU4002001A (en) * 2000-03-01 2001-09-12 Med Immune Inc High potency recombinant antibodies and method for producing them
AU784677B2 (en) * 2000-03-02 2006-05-25 Abgenix, Inc. Human monoclonal antibodies against oxidized LDL receptor and pharmaceutical uses thereof
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
DK1283214T3 (da) 2000-04-21 2007-06-11 Fuso Pharmaceutical Ind Hidtil ukendte kollektiner
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
RU2196605C2 (ru) * 2000-12-07 2003-01-20 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Способ получения растворимых конъюгатов биологически активных веществ
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
AU2002256624B2 (en) 2001-02-19 2007-12-06 Merck Patent Gmbh Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
JP2004537976A (ja) * 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP4729717B2 (ja) † 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
US7771722B2 (en) 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002324973A1 (en) * 2001-09-14 2003-04-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandandten Forschung E.V. Immunoglobulin having particular framework scaffold and methods of making and using
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
AU2002335808B2 (en) * 2001-10-15 2009-08-27 Ibc Pharmaceuticals Affinity enhancement agents
EP1441766B1 (en) * 2001-10-16 2011-09-14 MacroGenics West, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
DE60226641D1 (de) * 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
JP2005512043A (ja) * 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 治療剤産物の発見
ATE374944T1 (de) * 2001-12-03 2007-10-15 Abgenix Inc Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003092597A2 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
SG187991A1 (en) * 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003240790A1 (en) 2002-05-28 2003-12-12 Pharmacia Corporation Antibody peg positional isomers, compositions comprising same, and use thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1539793A4 (en) 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8071321B2 (en) 2002-08-29 2011-12-06 Cytocure Llc Methods for up-regulating antigen expression in tumors
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
WO2004039845A1 (en) * 2002-10-31 2004-05-13 Universita'degli Studi Di Roma 'la Sapienza' Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US7405061B2 (en) * 2002-11-13 2008-07-29 Raven Biotechnologies, Inc. Antigen PIPA and antibodies that bind thereto
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
EP1575516B1 (en) 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
ES2388280T3 (es) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
MXPA05007615A (es) 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
US7575747B2 (en) * 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
DK1631312T3 (da) 2003-04-23 2009-01-19 Medarex Inc Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2005010040A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR101672664B1 (ko) * 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
DK1656391T3 (da) 2003-08-13 2011-01-03 Pfizer Prod Inc Modificerede humane IGF-1R antistoffer
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20050048617A1 (en) * 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
EP1695093A1 (en) * 2003-12-05 2006-08-30 multimmune GmbH Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
EP1712566A4 (en) 2004-01-19 2007-09-12 Medical & Biol Lab Co Ltd INFLAMMATORY CYTOKINE INHIBITOR
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
EP1786463A4 (en) 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
KR20150041193A (ko) 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
EP2476427B1 (en) * 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
EA013821B1 (ru) 2005-05-25 2010-08-30 Кьюрдм, Инк. Проостровковые пептиды человека, их производные и аналоги и способы их применения
US8911733B2 (en) 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
DK2390267T3 (da) * 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ567043A (en) 2005-09-29 2012-08-31 Eisai R&D Man Co Ltd T-cell adhesion molecule and antibody thereto for inhibiting interaction between TARM and TARM-L
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
WO2007056161A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
EP1965827B1 (en) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Treatment of conditions involving demyelination
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
PT1976880T (pt) 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
JP2009523739A (ja) 2006-01-20 2009-06-25 ウィメンズ アンド チルドレンズ ヘルス リサーチ インスティテュート インコーポレーティッド 骨の病変の処置、予防、および診断の方法
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ596295A (en) 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20090258001A1 (en) * 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
AU2007281876B2 (en) * 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
TWI498137B (zh) 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP3018144A1 (en) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
PL3339445T3 (pl) 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5279504B2 (ja) 2006-11-17 2013-09-04 一般財団法人阪大微生物病研究会 神経伸長促進剤および伸長阻害剤
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
WO2008152446A2 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
KR20140119831A (ko) 2006-12-07 2014-10-10 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
US8680252B2 (en) 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
RU2493167C2 (ru) 2006-12-18 2013-09-20 Дженентек, Инк. АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8557533B2 (en) 2007-02-01 2013-10-15 Helmut Jonuleit Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
SG196697A1 (en) 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
WO2008143666A2 (en) 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
ES2534434T3 (es) 2007-08-30 2015-04-22 Curedm Group Holdings, Llc Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CA2736661A1 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
EP3750554A3 (en) 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
EP2650308A3 (en) * 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2586795B1 (en) 2007-10-05 2018-05-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0819195A2 (pt) 2007-11-05 2017-05-23 Medimmune Llc métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR101603109B1 (ko) 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
DK2222706T4 (en) 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
JP5817034B2 (ja) 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体及びその使用
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
WO2009088105A1 (en) * 2008-01-11 2009-07-16 Gene Techno Science Co., Ltd. HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
US20100303828A1 (en) 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102027017A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
AU2009224690B2 (en) 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
PL2262838T3 (pl) 2008-03-13 2016-10-31 Środek do leczenia choroby
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
WO2009119794A1 (ja) 2008-03-27 2009-10-01 タカラバイオ株式会社 感染症予防、治療剤
CA2720013C (en) 2008-04-03 2016-02-16 Bart De Strooper Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CA2721716C (en) 2008-04-24 2019-09-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
AU2009256397B2 (en) 2008-05-29 2014-06-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression and assembly of human group C rotavirus-like particles and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
ES2595362T3 (es) 2008-06-16 2016-12-29 Patrys Limited Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
HUE038432T2 (hu) * 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
JP5692746B2 (ja) 2008-08-07 2015-04-01 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP4180458A1 (en) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP2382238A1 (en) 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010085510A1 (en) 2009-01-20 2010-07-29 Zadeh Homayoun H Antibody mediated osseous regeneration
CN102369217A (zh) 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
EP3495000A1 (en) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
KR101667227B1 (ko) 2009-03-10 2016-10-18 가부시키가이샤 진 테크노 사이언스 인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
MX2011009704A (es) * 2009-03-16 2011-09-28 Cephalon Australia Pty Ltd Anticuerpos humanizados con actividad anti-tumor.
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
US20120070450A1 (en) 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
KR101852204B1 (ko) 2009-06-05 2018-04-26 아블린쓰 엔.브이. 기도 감염의 예방 및/또는 치료를 위한 일가, 이가 및 삼가 항 인간 호흡기 세포융합 바이러스 (ｈｒｓｖ) 나노바디 구조물
WO2010142603A1 (en) 2009-06-08 2010-12-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2764545C (en) 2009-06-15 2019-05-14 Katholieke Universiteit Leuven, K.U.Leuven R&D Bace1 inhibitory antibodies
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
JP5946766B2 (ja) 2009-07-03 2016-07-06 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ Ｈｉｖワクチン組成物における使用又は診断手段としての使用のためのｈｉｖ関連ペプチドの組合せ又は融合物
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
EP2473851A1 (en) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UA106771C2 (uk) 2009-10-16 2014-10-10 Ле Лаборатуар Сервьє Моноклональні антитіла до прогастрину та їх використання
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493929B1 (en) 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr antibodies and their uses
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
AU2010313318A1 (en) 2009-10-30 2012-04-12 Abbott Biotherapeutics Corp. Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
EP2496257A4 (en) 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd TREATING CANCER WITH MUTATED KRAS OR BRAF GENES
WO2011057188A1 (en) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2506869A1 (en) 2009-12-04 2012-10-10 VIB vzw Arf6 as a new target for treating alzheimer's disease
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
KR101570404B1 (ko) 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2550297B1 (en) 2010-03-25 2019-01-23 UCB Biopharma SPRL Disulfide stabilized dvd-lg molecules
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US8986689B2 (en) 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
US20130034543A1 (en) 2010-04-19 2013-02-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Modulating xrn1
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
WO2011154485A1 (en) 2010-06-10 2011-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
ES2961381T3 (es) * 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
DK3459558T3 (da) 2010-06-25 2020-11-02 Univ Aston Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
EA028515B1 (ru) 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
EP2614080A1 (en) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
CA2813133C (en) 2010-10-01 2023-10-31 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US9771416B2 (en) 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
PL2634194T3 (pl) 2010-10-29 2018-12-31 Perseus Proteomics Inc Przeciwciało przeciwko cdh3 o dużej zdolności do internalizacji
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
MX373443B (es) 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012167346A1 (en) 2011-06-10 2012-12-13 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anti-ricin antibodies and uses thereof
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
RU2640025C2 (ru) 2011-07-13 2017-12-25 Эббви Инк. Способы и композиции для лечения астмы с использованием антител против il-13
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
BR112014006175B1 (pt) 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
BR112014006405A2 (pt) 2011-09-21 2017-04-04 Fujirebio Kk anticorpo, conjunto, e, método para medir um complexo de afinidade
EP2758422A1 (en) 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Modified albumin-binding domains and uses thereof to improve pharmacokinetics
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
EP2771360A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Immunobinders directed against sclerostin
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2776022A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2599496A1 (en) 2011-11-30 2013-06-05 Kenta Biotech AG Novel targets of Acinetobacter baumannii
WO2013085972A1 (en) 2011-12-05 2013-06-13 X-Body, Inc. Pdgf receptor beta binding polypeptides
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP2800583A1 (en) 2012-01-02 2014-11-12 Novartis AG Cdcp1 and breast cancer
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
DK2804878T3 (en) 2012-01-20 2018-12-17 Genzyme Corp ANTI-CXCR3 ANTIBODIES
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AR090352A1 (es) 2012-03-28 2014-11-05 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EP2831112A1 (en) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2013172951A1 (en) 2012-05-15 2013-11-21 Morphotek, Inc. Methods for treatment of gastric cancer
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
AU2013289971A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Enhancing activity of CAR T cells by co-introducing a bispecific antibody
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
NO2760138T3 (no) 2012-10-01 2018-08-04
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP2906597B1 (en) 2012-10-15 2020-04-08 Medimmune Limited Antibodies to amyloid beta
CN104870472A (zh) 2012-10-24 2015-08-26 加拿大国家研究委员会 抗空肠弯曲杆菌抗体及其用途
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
HRP20170743T1 (hr) 2012-11-20 2017-07-28 Sanofi Anti-ceacam5 protutijela i njihova uporaba
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014083379A1 (en) 2012-11-30 2014-06-05 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
EP3400961B1 (en) 2012-12-27 2021-02-24 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
RU2015126663A (ru) 2013-01-28 2017-03-10 Эвек Инк. Гуманизированное антитело против hmgb1 или антиген-связывающий фрагмент указанного антитела
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
LT2958943T (lt) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
US20150010538A1 (en) 2013-03-15 2015-01-08 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
JP2016515524A (ja) 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
BR112015022119A2 (pt) 2013-03-15 2017-08-29 Abbvie Biotherapeutics Inc Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
MX376808B (es) 2013-05-24 2025-03-07 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EA033403B1 (ru) 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US20160193308A1 (en) 2013-09-04 2016-07-07 Osaka University Dpp-4-targeting vaccine for treating diabetes
CN104418947A (zh) 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
RU2671089C2 (ru) 2013-09-16 2018-10-29 Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
CN111443069A (zh) 2013-10-28 2020-07-24 多茨技术公司 过敏原检测
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
CA2929386C (en) 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
WO2015095143A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ724869A (en) 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
AU2014385799B2 (en) 2014-03-06 2020-10-22 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
NZ724868A (en) 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
KR102399028B1 (ko) 2014-03-21 2022-05-17 엑스-바디 인코포레이티드 이중-특이적 항원-결합 폴리펩티드
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
WO2015158851A1 (en) 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
EP3804745A1 (en) 2014-04-25 2021-04-14 The Brigham and Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3137114B8 (en) 2014-04-30 2021-08-04 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
EP3154579A1 (en) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research New treatment against influenza virus
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102641268B1 (ko) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
ES2715413T3 (es) 2014-07-29 2019-06-04 Cellectis Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015311951B2 (en) 2014-09-02 2021-04-08 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
WO2016054354A1 (en) * 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
US10098973B2 (en) 2014-10-10 2018-10-16 National Research Council Of Canada Anti-tau antibody and uses thereof
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
ES2910227T3 (es) 2014-10-31 2022-05-12 Univ Pennsylvania Composición y métodos para la estimulación y expansión de células T
AU2015338984A1 (en) 2014-10-31 2017-04-27 The Trustees Of The University Of Pennsylvania Methods and compositions for modified T cells
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11072644B2 (en) 2014-11-12 2021-07-27 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
DK3029137T3 (en) 2014-12-06 2019-04-08 Gemoab Monoclonals Gmbh GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
CN111620861A (zh) 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
CA2969908A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
WO2016094602A1 (en) 2014-12-10 2016-06-16 Tufts University Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
EP3233897B1 (en) 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
CA2970986C (en) * 2014-12-19 2021-10-26 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016120218A1 (en) 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
EP4223873A3 (en) 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016149096A1 (en) 2015-03-13 2016-09-22 President And Fellows Of Harvard College Determination of cells using amplification
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US20180071413A1 (en) 2015-04-07 2018-03-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-invasive imaging of tumor pd-l1 expression
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
PE20180251A1 (es) 2015-04-28 2018-02-02 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNIION A RGMa Y SU USO
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
EA037092B1 (ru) 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
WO2017005847A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
MX2018001776A (es) 2015-08-11 2018-06-06 Cellectis Celulas para inmunoterapia modificadas geneticamente para dirigirse al antigeno cd38 y para la inactivacion del gen cd38.
CN108348551A (zh) 2015-08-28 2018-07-31 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
CN108463247B (zh) 2015-10-28 2022-04-12 耶鲁大学 人源化的抗dkk2抗体和其用途
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
EP3370764A4 (en) 2015-11-05 2019-07-17 The Regents of The University of California Cells labeled with lipid conjugates and method of use thereof
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
ES2810755T3 (es) 2015-11-30 2021-03-09 Abbvie Inc Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
SI3389699T1 (sl) 2015-12-15 2024-07-31 OncoC4, Inc. Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
TN2018000197A1 (en) 2015-12-31 2019-10-04 Syncerus S A R L Compositions and methods for assessing the risk of cancer occurrence
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
ES2970868T3 (es) 2016-03-02 2024-05-31 Idexx Lab Inc Métodos y composiciones para la detección y diagnóstico de enfermedad renal y enfermedad periodontal
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
AR107893A1 (es) 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
KR102571700B1 (ko) 2016-03-17 2023-08-29 누맙 세러퓨틱스 아게 항TNFα 항체 및 이의 기능성 단편
EP3219726B1 (en) 2016-03-17 2020-12-02 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
JP7184746B2 (ja) 2016-03-17 2022-12-06 ヌマブ イノヴェイション アーゲー 抗ＴＮＦα抗体およびそれらの機能的断片
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
WO2017158079A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
WO2017184707A1 (en) 2016-04-19 2017-10-26 President And Fellows Of Harvard College Immobilization-based systems and methods for genetic analysis and other applications
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
CA3022494A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
HUE053332T2 (hu) 2016-05-17 2021-06-28 Abbvie Biotherapeutics Inc Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
UA123111C2 (uk) 2016-05-27 2021-02-17 Еббві Байотерапьютікс Інк. Антитіло до cd40 та його застосування
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3484516A4 (en) 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center MULTIPLE SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOP BINDING FOR TREATING CANCER
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3031289A1 (en) 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells to treat cancer
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
CN110214150A (zh) 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
HRP20201993T1 (hr) 2016-09-14 2021-02-05 Abbvie Biotherapeutics Inc. Protutijela protiv pd-1
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
PL3328887T3 (pl) 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
RU2019114863A (ru) 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
BR112019012328A2 (pt) 2016-12-15 2019-11-19 Abbvie Biotherapeutics Inc anticorpos anti-ox40 e seus usos
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
KR20190095943A (ko) 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
JP7211952B2 (ja) 2017-01-05 2023-01-24 ネトリス ファーマ ネトリン－１干渉薬及び免疫チェックポイント阻害薬による併用治療
KR102646046B1 (ko) 2017-01-06 2024-03-08 바이오션, 인코포레이티드 Erbb2 항체 및 이의 용도
CN110291109B (zh) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
UA126571C2 (uk) 2017-01-24 2022-11-02 Ай-Маб Байофарма Юес Лімітед Антитіло до cd73 та його застосування
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
EP3579871A4 (en) 2017-02-07 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS OF TREATMENT FOR ACTIVE BECHTEREW'S LIVER
CA3053774A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3583126B1 (en) 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
KR20190133198A (ko) 2017-03-27 2019-12-02 셀진 코포레이션 면역원성의 감소를 위한 방법 및 조성물
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CA3058282A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
MX2019012136A (es) 2017-04-14 2020-07-20 Gamamabs Pharma Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US12569497B2 (en) 2017-04-27 2026-03-10 The University Of Hong Kong Use of HCN inhibitors for treatment of cancer
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
CA3063051A1 (en) 2017-05-10 2018-11-15 The Wistar Institute Of Anatomy And Biology Optimized nucleic acid antibody constructs
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018208553A1 (en) 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
WO2018218207A1 (en) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP7394628B2 (ja) 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
EP3638295A1 (en) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
CN111491661B (zh) 2017-07-27 2024-11-01 诺莫坎制药有限责任公司 M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
JP7241080B2 (ja) 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
AU2018335955B2 (en) 2017-09-21 2024-12-12 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3694883A1 (en) 2017-10-12 2020-08-19 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019099440A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
BR112020013086A2 (pt) 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
EP3746123A4 (en) 2018-02-01 2021-12-01 Memorial Sloan-Kettering Cancer Center ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
CN111727058A (zh) 2018-02-23 2020-09-29 卡瑟里克斯私人有限公司 靶向tag-72的t细胞疾病治疗
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
CA3093838A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
EP3773739A1 (en) 2018-04-12 2021-02-17 MediaPharma S.r.l. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
WO2019204912A1 (en) 2018-04-24 2019-10-31 National Research Council Of Canada Blood-brain barrier transmigrating therapeutic compounds and uses thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
US12458705B2 (en) 2018-06-12 2025-11-04 Angiex, Inc. Antibody-oligonucleotide conjugates
AU2019289646B2 (en) 2018-06-18 2025-10-23 Innate Pharma Compositions and methods for treating cancer
SG11202012312UA (en) 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
JP2021527693A (ja) 2018-06-21 2021-10-14 ユマニティ セラピューティクス，インコーポレーテッド 神経学的障害の治療及び予防のための組成物及び方法
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
WO2020002579A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
BR112021000300A2 (pt) 2018-07-10 2021-04-06 Mitsubishi Tanabe Pharma Corporation Método de prevenção ou tratamento para neuropatia periférica ou doença acompanhada de dor em que neuropatia periférica ou transtorno de astrocito é reconhecido
CN112424231B (zh) 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
CN112739340B (zh) 2018-07-23 2025-05-13 海德堡医药研究有限责任公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
MX2021002225A (es) 2018-08-30 2021-07-16 Tcr2 Therapeutics Inc Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
US12398402B2 (en) 2018-09-12 2025-08-26 Fred Hutchinson Cancer Center Reducing CD33 expression to selectively protect therapeutic cells
CA3153959A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020056522A1 (en) 2018-09-21 2020-03-26 National Research Council Of Canada Intrabodies for reducing fut8 activity
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856773A1 (en) 2018-09-28 2021-08-04 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
US12129305B2 (en) 2018-10-25 2024-10-29 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
CA3118026A1 (en) 2018-10-31 2020-05-07 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
JP7609775B2 (ja) 2018-12-14 2025-01-07 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
EP3898687A1 (en) 2018-12-20 2021-10-27 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
CA3127776A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
US12241061B2 (en) 2019-02-04 2025-03-04 National University Corporation Ehime University CAR library and scFv manufacturing method
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
KR20210142638A (ko) 2019-02-22 2021-11-25 우한 이지 바이오파마 씨오., 엘티디. Cd3 항원 결합 단편 및 이의 응용
WO2020168554A1 (zh) 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 改造的Fc片段，包含其的抗体及其应用
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
CA3131391A1 (en) 2019-02-27 2020-09-03 Angiex, Inc. Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
KR20210152472A (ko) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 Cd22 항체 및 이를 사용하는 방법
AU2020243076A1 (en) 2019-03-20 2021-10-14 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
EP3947457A1 (en) 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
AU2019456113A1 (en) 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
EP4004050A2 (en) 2019-07-30 2022-06-01 QLSF Biotherapeutics Inc. Multispecific binding compound that bind to lfrrc15 and cd3
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
CN114206929B (zh) 2019-09-03 2023-12-22 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
UA129546C2 (uk) 2019-09-16 2025-05-28 Опсідіо, Ллк Антитіла проти фактора стовбурових клітин і способи їх застосування
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
US11802151B2 (en) 2019-11-04 2023-10-31 Code Biotherapeutics, Inc. Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
WO2021099600A1 (en) 2019-11-22 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
US20230227559A1 (en) 2019-12-10 2023-07-20 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN118767130A (zh) 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
JP7709165B2 (ja) 2020-01-15 2025-07-16 国立大学法人大阪大学 認知症の予防又は治療剤
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4100435A1 (en) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
EP4103610A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
EP4103608A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
EP4103611B1 (en) 2020-02-13 2024-03-27 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
EP4103612A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9
EP4103609A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN115515643A (zh) 2020-02-28 2022-12-23 建新公司 用于优化的药物缀合的经修饰的结合多肽
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
US20230126689A1 (en) 2020-03-06 2023-04-27 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A4 (en) 2020-03-31 2024-06-26 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
AU2021258464A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil
WO2021214221A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
BR112022020497A2 (pt) 2020-04-24 2022-12-06 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfox
AU2021258465A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates and cetuximab
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
CN116157510A (zh) 2020-06-17 2023-05-23 詹森生物科技公司 用于制造多能干细胞的材料和方法
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
WO2022012680A1 (en) 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
EP4183416A4 (en) 2020-07-17 2025-08-27 Mitsubishi Tanabe Pharma Corp AGENT FOR PREVENTING OR TREATING MUSCULAR DISEASE
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
JP7823021B2 (ja) 2020-08-07 2026-03-03 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｐｄ－ｌ１抗体及びその応用
CA3190987A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
MX2023002330A (es) 2020-09-04 2023-03-21 Merck Patent Gmbh Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
CA3254914A1 (en) 2020-10-07 2026-03-02 Zoetis Services Llc Anti-ngf antibodies and methods of use thereof
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45
US20240084014A1 (en) 2020-10-16 2024-03-14 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
CA3197465A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
EP4242232A4 (en) 2020-11-06 2024-09-11 Bio-Thera Solutions, Ltd. BISPECIFIC ANTIBODY AND ITS USE
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
MX2023005979A (es) 2020-11-20 2023-08-11 Scherer Technologies Llc R P Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco.
EP4255574A1 (en) 2020-12-01 2023-10-11 Aptevo Research and Development LLC Heterodimeric psma and cd3-binding bispecific antibodies
MX2023006649A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos contra interleucina-22.
KR20230117588A (ko) 2020-12-07 2023-08-08 유씨비 바이오파마 에스알엘 다중특이적 항체 및 항체 조합
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022143794A1 (zh) 2020-12-30 2022-07-07 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其制备方法和应用
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
US20240141026A1 (en) 2021-03-04 2024-05-02 Centre National De La Recherche Scientifique Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
MX2023010837A (es) 2021-03-17 2023-09-29 Receptos Llc Métodos de tratamiento de la dermatitis atopica.
IL307168A (en) 2021-03-26 2023-11-01 Janssen Biotech Inc Humanized antibodies against paired helical strands of TAU protein and their uses
CN117425484A (zh) 2021-03-26 2024-01-19 阿奇利克斯股份有限公司 多功能免疫细胞疗法
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
EP4362977A1 (en) 2021-06-29 2024-05-08 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
US20240368260A1 (en) 2021-07-29 2024-11-07 Institut National De La Sante Et De La Recherche Medicale HUMANIZED ANTI-HUMAN ßIG-H3 PROTEIN AND USES THEREOF
CN117642421A (zh) 2021-07-29 2024-03-01 武田药品工业株式会社 特异性靶向间皮素的工程化免疫细胞以及其用途
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CN118019548A (zh) 2021-08-06 2024-05-10 蒙彼利埃癌症研究所 用于治疗癌症的方法
AU2022325950A1 (en) 2021-08-11 2024-02-22 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
US12467921B2 (en) 2021-08-31 2025-11-11 Versitech Limited Antibodies and assays for detection of Burkholderia mallei
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
JP2024534661A (ja) 2021-09-30 2024-09-20 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｂ７－ｈ３抗体及びその応用
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
EP4426736A1 (en) 2021-11-05 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
EP4436998A1 (en) 2021-11-24 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
CN116333135A (zh) 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
CN119487076A (zh) 2022-03-09 2025-02-18 默克专利股份公司 抗ceacam5抗体及其缀合物和用途
EP4489791A1 (en) 2022-03-09 2025-01-15 Merck Patent GmbH Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
AU2023232448A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
KR20240159846A (ko) 2022-03-11 2024-11-06 얀센 파마슈티카 엔브이 다중특이적 항체 및 이의 용도
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
AU2023242470A1 (en) 2022-03-29 2024-10-10 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
US20250333498A1 (en) 2022-06-01 2025-10-30 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and antibody-drug conjugate and use thereof
EP4536290A1 (en) 2022-06-08 2025-04-16 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
EP4554969A1 (en) 2022-07-15 2025-05-21 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
CN119546339A (zh) 2022-07-15 2025-02-28 丹尼斯科美国公司 用于产生单克隆抗体的方法
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
AU2023324667A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
EP4590335A1 (en) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
CA3264339A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen-binding molecules and their uses
CN120129696A (zh) 2022-09-01 2025-06-10 乔治亚大学研究基金公司 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
US20260078192A1 (en) 2022-09-06 2026-03-19 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
JPWO2024053742A1 (no) 2022-09-09 2024-03-14
CN120225559A (zh) 2022-09-12 2025-06-27 国家健康与医学研究院 新型抗itgb8抗体及其用途
EP4587123A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590705A1 (en) 2022-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
AR130982A1 (es) 2022-11-07 2025-02-05 Univ Osaka Agente preventivo o terapéutico para enfermedades asociadas con la agregación de proteínas anormales
CA3273660A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL TREATMENT FOR FIBROMYALGIA
GB202217923D0 (en) 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
CN120530134A (zh) 2022-12-22 2025-08-22 朱利叶斯-马克西米利维尔茨堡大学 用作凝血剂的抗体
WO2024138144A1 (en) * 2022-12-22 2024-06-27 The Medical College Of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
TW202448960A (zh) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
GB202301949D0 (en) 2023-02-10 2023-03-29 Coding Bio Ltd CLL1 and/or CD33 binding molecules
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
CN120858111A (zh) 2023-02-27 2025-10-28 奈特里斯药物公司 用于治疗子宫内膜异位症和相关疼痛的抗轴突导向因子-1单克隆抗体
AU2024228735A1 (en) 2023-03-01 2025-10-16 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
EP4680344A1 (en) 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194455A1 (en) 2023-03-23 2024-09-26 Sanofi CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract
EP4688830A1 (en) 2023-04-07 2026-02-11 Commissariat à l'Energie Atomique et aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
AU2024286132A1 (en) 2023-06-05 2026-01-22 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
EP4727586A1 (en) 2023-06-13 2026-04-22 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
EP4731681A1 (en) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025049272A1 (en) 2023-08-25 2025-03-06 The Broad Institute, Inc. Card9 variant polypeptide and antibodies directed thereto
WO2025061994A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025085805A1 (en) 2023-10-20 2025-04-24 OncoC4, Inc. Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
GB202317065D0 (en) 2023-11-07 2023-12-20 Coding Bio Ltd BCMA binding molecules
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
AR134580A1 (es) 2023-12-08 2026-01-28 Janssen Biotech Inc ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
EP4574174A1 (en) * 2023-12-19 2025-06-25 Jack Elands Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
TW202600175A (zh) 2024-02-15 2026-01-01 德商馬克專利公司 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
TW202602914A (zh) 2024-04-05 2026-01-16 比利時商Ｕｃｂ生物製藥公司 抗體
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
TW202547865A (zh) 2024-05-17 2025-12-16 比利時商Ｕｃｂ生物製藥公司 具有il-11結合特異性的抗體
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
TW202606759A (zh) 2024-08-02 2026-02-16 比利時商Ｕｃｂ生物製藥公司 抗Gremlin-1抗體的調配物
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026044177A1 (en) 2024-08-23 2026-02-26 Janssen Biotech, Inc. Methods of treatment with gprc5d antibodies with enhanced effector function
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
CN121896173A (zh) 2024-10-21 2026-04-21 深圳市湾岛细胞科技有限公司 表达外源肌苷单磷酸脱氢酶的真核细胞
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026096383A1 (en) 2024-10-28 2026-05-07 The Broad Institute, Inc. Compositions and methods for inducing phagocytosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) * 1989-12-18 1991-11-05 Oronzio Denora S.A. Method and apparatus for cathodic protection
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
CA2736076A1 (en) * 1991-03-18 1992-09-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
JPH06202412A (ja) * 1992-12-26 1994-07-22 Canon Inc 画像形成装置
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5535089A (en) * 1994-10-17 1996-07-09 Jing Mei Industrial Holdings, Ltd. Ionizer

Also Published As

Publication number Publication date
ES2074701T3 (es) 1995-09-16
DK0460171T3 (da) 1995-08-28
NO985468L (no) 1991-10-21
FI913926A0 (fi) 1991-08-20
WO1991009967A1 (en) 1991-07-11
EP0460171A1 (en) 1991-12-11
EP0626390A1 (en) 1994-11-30
AU7033091A (en) 1991-07-24
US20050123534A1 (en) 2005-06-09
ATE129017T1 (de) 1995-10-15
DE69033857T2 (de) 2002-09-12
ATE159299T1 (de) 1997-11-15
RO114980B1 (ro) 1999-09-30
GB9318911D0 (en) 1993-10-27
HU217693B (hu) 2000-03-28
US7244615B2 (en) 2007-07-17
DK0460167T3 (da) 1995-11-20
FI990875A0 (fi) 1999-04-19
ZA9110129B (en) 1993-06-23
NO316074B1 (no) 2003-12-08
US7262050B2 (en) 2007-08-28
FI108777B (fi) 2002-03-28
US5929212A (en) 1999-07-27
AU6974091A (en) 1991-07-24
KR100191152B1 (ko) 1999-06-15
HU912752D0 (en) 1992-01-28
CA2050479A1 (en) 1991-06-22
NO316076B1 (no) 2003-12-08
CA2046904C (en) 2003-12-02
NO985468D0 (no) 1998-11-23
JP3452062B2 (ja) 2003-09-29
CA2046904A1 (en) 1991-06-22
DK0460178T3 (da) 1997-12-22
JPH04505398A (ja) 1992-09-24
GB2268744B (en) 1994-05-11
NO913229D0 (no) 1991-08-19
JPH11243955A (ja) 1999-09-14
HU912751D0 (en) 1992-01-28
EP0626390B1 (en) 2001-11-14
FI913927A0 (fi) 1991-08-20
FI109768B (fi) 2002-10-15
HUT58824A (en) 1992-03-30
EP0460178B1 (en) 1997-10-15
BG95018A (bg) 1993-12-24
AU649645B2 (en) 1994-06-02
AU6461294A (en) 1994-12-22
JP3242913B2 (ja) 2001-12-25
GB8928874D0 (en) 1990-02-28
RU2112037C1 (ru) 1998-05-27
RO114298B1 (ro) 1999-03-30
NO913271L (no) 1991-08-20
CA2037607A1 (en) 1992-09-07
BR9007197A (pt) 1992-01-28
NO985467D0 (no) 1998-11-23
NO913228D0 (no) 1991-08-19
WO1991009968A1 (en) 1991-07-11
HUT58372A (en) 1992-02-28
ATE124459T1 (de) 1995-07-15
GR3025781T3 (en) 1998-03-31
USRE50178E1 (en) 2024-10-22
US20060073136A1 (en) 2006-04-06
GB9117611D0 (en) 1991-10-02
FI990875L (fi) 1999-04-19
ES2079638T3 (es) 1996-01-16
ES2165864T3 (es) 2002-04-01
ES2112270T3 (es) 1998-04-01
AU664801B2 (en) 1995-11-30
HUT60786A (en) 1992-10-28
DE69022982D1 (de) 1995-11-16
DK0626390T3 (da) 2002-03-11
JPH04506458A (ja) 1992-11-12
EP0460178A1 (en) 1991-12-11
GB2246781A (en) 1992-02-12
FI108776B (fi) 2002-03-28
GB9117612D0 (en) 1991-11-20
EP0460167A1 (en) 1991-12-11
FI913932A0 (fi) 1991-08-20
ATE208794T1 (de) 2001-11-15
RO114232B1 (ro) 1999-02-26
GB2246781B (en) 1994-05-11
US7241877B2 (en) 2007-07-10
NO913271D0 (no) 1991-08-20
AU646009B2 (en) 1994-02-03
US20040076627A1 (en) 2004-04-22
EP0460167B1 (en) 1995-10-11
NO913229L (no) 1991-10-21
EP0460171B1 (en) 1995-06-28
KR100198478B1 (en) 1999-06-15
DE69031591D1 (de) 1997-11-20
GB2268744A (en) 1994-01-19
DE69020544T2 (de) 1996-01-18
US20050202529A1 (en) 2005-09-15
NO985467L (no) 1991-10-21
EP0620276A1 (en) 1994-10-19
AU631481B2 (en) 1992-11-26
NO310560B1 (no) 2001-07-23
WO1991009966A1 (en) 1991-07-11
US20040202662A1 (en) 2004-10-14
KR920701465A (ko) 1992-08-11
US7244832B2 (en) 2007-07-17
KR100197956B1 (ko) 1999-06-15
AU7048691A (en) 1991-07-24
CA2050479C (en) 1997-03-25
FI108917B (fi) 2002-04-30
HU215383B (hu) 2000-03-28
JPH05500312A (ja) 1993-01-28
DE69020544D1 (de) 1995-08-03
US20050136054A1 (en) 2005-06-23
DE69022982T2 (de) 1996-03-28
BG60462B1 (bg) 1995-04-28
GB2246570B (en) 1994-05-11
US20040071693A1 (en) 2004-04-15
CA2037607C (en) 2005-05-24
DE69031591T2 (de) 1998-03-12
DE69033857D1 (de) 2001-12-20
GR3017734T3 (en) 1996-01-31
US20060073137A1 (en) 2006-04-06
US20060029593A1 (en) 2006-02-09
GB2246570A (en) 1992-02-05

Similar Documents

Publication Publication Date Title
NO913228D0 (no) Antistoffer og fremgangsmaate for deres fremstilling.
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
DK0727435T3 (da) Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse
GR900100550A (el) Μία μέ?οδος για την αναστολή της αντιγραφής ιού σε κύτταρα ?ηλαστικών χρησιμοποιώντας συζυγείς πρωτεϊνης αντιιού φυτολάκκας - μονοκλωνικού αντισώματος.

Legal Events

Date Code Title Description
MK1K Patent expired